Physician profile
Mark P Karavan
NPI 1528054244
$2,337.20
in general payments reported to CMS, 2019-2025
16 companies · $513 in 2025
The $513 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8.22 · 2021: $20.78 · 2022: $590 · 2023: $697 · 2024: $507 · 2025: $513.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,718.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $561.36 | 2022-2025 | Watchman Flx, Watchman Access System, Cds - Mct/Cem Monitoring |
| Shockwave Medical, INC | $306.96 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Abiomed | $298.05 | 2022-2023 | Impella |
| Kiniksa Pharmaceuticals International, Plc | $189.80 | 2024 | Arcalyst |
| Novartis Pharmaceuticals Corporation | $158.99 | 2022-2025 | |
| Cardiovascular Systems INC. | $141.00 | 2023 | Diamondback Coronary |
| Exactech, INC. | $119.88 | 2022 | |
| Amgen INC. | $118.01 | 2023-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.82 | 2023-2025 | Jardiance |
| Pfizer INC. | $111.38 | 2023-2025 | |
| Atricure, INC. | $73.50 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $48.50 | 2019-2025 | Lifevest |
| Astrazeneca Pharmaceuticals LP | $31.00 | 2023-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $28.20 | 2024-2025 | Eliquis |
| Medtronic, INC. | $20.78 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cvrx, INC. | $11.97 | 2025 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Karavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.